author-photo

Milvia Zambetti

Vita-Salute San Raffaele University

110

Papers

7202

Citations

Citation Trend

Filter By

Papers (81) Sort By

Journal Conference Others

Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype

2019 Ejso
Show All
- Source
- Cite
- Save
Citations (10)
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study

2018 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (5)
Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial

2018 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (52)
Abstract P1-13-06: Safety of trastuzumab in the subcutaneous formulation for the treatment of HER2 positive early breast cancer (eBC) patients: Primary results of SCHEARLY trial

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

2018 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (352)
Freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by CMF as adjuvant or primary systemic therapy: 10-yr results of a randomized phase III European Cooperative Trial in Operable Breast Cancer (ECTO).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
A dendritic metagene that predicts prognosis and endocrine resistance in breast cancer.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Abstract P4-21-39: Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: Effect on Ki67 during and after treatment. A phase II Michelangelo study

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (5)
Proliferation-, estrogen-, and T-cell-related metagenes to predict outcome after adjuvant/neoadjuvant chemotherapy for operable breast cancer in the ECTO trial.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Abstract P4-04-04: Triple-negative (TN) and HER2+ breast cancers (BC) have different immune milieu in primary and metastatic tumors

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)